SCM
CPRX

Sterling Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Sterling Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Sell
413
-1,777
-81% -$52.4K ﹤0.01% 2086
2026
Q1 		$54.2K Sell
2,190
-825
-27% -$19.7K ﹤0.01% 1603
2025
Q4 		$70.4K Buy
3,015
+2,735
+977% +$60.9K ﹤0.01% 1667
2025
Q3 		$5.52K Hold
280
– – ﹤0.01% 2743
2025
Q2 		$6.08K Buy
280
+163
+139% +$3.85K ﹤0.01% 2417
2025
Q1 		$2.84K Buy
117
+4
+4% +$90 ﹤0.01% 2436
2024
Q4 		$2.36K Hold
113
– – ﹤0.01% 2739
2024
Q3 		$2.25K Buy
+113
New +$2.1K ﹤0.01% 2134

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sterling Capital Management's CPRX Position: Q2 2026 in Review

Sterling Capital Management reduced its Catalyst Pharmaceutical (CPRX) stake by 81% in Q2 2026, selling an estimated $52.4K and leaving 413 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #2086.

Sterling Capital Management first reported a position in CPRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $70.4K in Q4 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Sterling Capital Management held 413 shares of Catalyst Pharmaceutical worth $13K as of Q2 2026.
  • Sterling Capital Management sold 1,777 Catalyst Pharmaceutical shares in Q2 2026, an estimated $52.4K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2086 holding.
  • Sterling Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Catalyst Pharmaceutical position peaked at $70.4K in Q4 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.